WHY BENLYSTA?

Dr. Grace Wright, Rheumatologist

Paid consultant to GSK at the time of filming.

  • TRANSCRIPT

    DR. WRIGHT: I’m Doctor Grace Wright, a Rheumatologist in New York City.

    ON-SCREEN TEXT: Dr. Grace Wright, Rheumatologist
    Paid consultant to GSK at the time of filming.

    ON-SCREEN TEXT: “Why BENLYSTA?”
    Stay tuned for Important Product Information

    ON-SCREEN TEXT: Dr. Grace Wright, Rheumatologist
    Paid consultant to GSK at the time of filming.

    DR. WRIGHT: So, if my peer were to ask me, “Why should I use BENLYSTA? Why should I use it earlier?”, I think back to the fact that our patients are living with a chronic disease – one that they will experience over the course of their lifetime – and if we can initiate therapy that can help to control that disease activity earlier, then I think that’s a good thing to do.

    ON-SCREEN TEXT: “Help control disease activity”

    DR. WRIGHT: When we look at the data, we now have years of data on efficacy, on safety. We have clinical trial data, we have real-world data, the kinds of data that we need to have a discussion with our patients about how this can work for them.

    ON-SCREEN TEXT: Years of data on BENLYSTA

    DR. WRIGHT: And so, if we just think through the data, and think about the impact that we can have on controlling disease activity, it just feels like the right thing to do to help our patients manage something that they have to live with for the rest of their lives.

    ON-SCREEN TEXT: “Help our patients”

    DR. WRIGHT: And so, I think it’s really important to put everything into context about that patient and what they experience and how we can help them improve their disease control.

    ON-SCREEN TEXT: BENLYSTAHCP.com

    DR. WRIGHT: Thank you for watching. Visit the BENLYSTA website for more information.

    VOICEOVER:
    IMPORTANT PRODUCT INFORMATION
    For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

    ON-SCREEN TEXT:
    IMPORTANT PRODUCT INFORMATION
    For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    ON-SCREEN TEXT:
    BENLYSTA
    (belimumab)
    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. | ©2021 GSK or licensor. BELVID220043 August 2022. Produced in USA.

You may also like

WHY BENLYSTA?

Dr. William Pendergraft, Nephrologist

WHY BENLYSTA?

Dr. Alvin Wells, Rheumatologist

JOIN US FOR
A LIVE WEBINAR

Paid consultants to GSK at the time of filming.